BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases
AC Roden, X Hu, S Kip, ERP Castellar… - The American journal …, 2014 - journals.lww.com
Pulmonary Langerhans cell histiocytosis (PLCH) has been postulated to be a smoking-
related non-neoplastic condition, distinct from extrapulmonary LCH, which is generally
regarded as a clonal, neoplastic process. Recent genomic studies demonstrated BRAF
V600E mutation in 38% to 57% of extrapulmonary LCH cases by polymerase chain reaction.
We evaluated the BRAF V600E expression by immunohistochemistry (IHC) in PLCH and
extrapulmonary LCH cases. We compared BRAF V600E expression in PLCH and …
related non-neoplastic condition, distinct from extrapulmonary LCH, which is generally
regarded as a clonal, neoplastic process. Recent genomic studies demonstrated BRAF
V600E mutation in 38% to 57% of extrapulmonary LCH cases by polymerase chain reaction.
We evaluated the BRAF V600E expression by immunohistochemistry (IHC) in PLCH and
extrapulmonary LCH cases. We compared BRAF V600E expression in PLCH and …